Navigation Links
Covagen Names Elias Papatheodorou Chief Business Officer
Date:4/14/2013

ZURICH-SCHLIEREN, Switzerland, April 15, 2013 /PRNewswire/ -- Covagen today announced the expansion of its senior management team with the appointment of Elias Papatheodorou as chief business officer. He brings 20 years of work experience including 13 years in the life science sector with a track record of fundraising and collaborative agreements.

Prior to joining Covagen, Mr. Papatheodorou was senior vice president business development and operations at Medigene where he led the business development efforts for the company's pipeline and technology and closed the Asian-Australian licensing agreement for Medigene's lead oncology asset to Syncore. Prior to Medigene, Mr. Papatheodorou was chief executive officer of Novosom where he completed a series of collaborative agreements with pharmaceutical companies in Europe, U.S. and Asia, led the company's fundraising activities and ultimately closed the sale of Novosom's Smarticles technology to Marina Biotech. Mr. Papatheodorou was also vice president of business development and marketing for the medical imaging company A.T.I. and held positions of increasing responsibility at The Coca-Cola Company and Philip Morris.

"We are fortunate to have someone with Elias' experience join our executive team, particularly as we continue to validate our bispecific FynomAb™ technology and prepare to bring our lead drug candidate COVA322, a bispecific TNF/IL-17A inhibitor, into the clinic," said Franz Hefti , chairman of the board of Covagen. "The flexibility of the architecture of our FynomAbs is unique in bispecific technology and Elias will play a key role in advancing discussions with potential partners."

Mr. Papatheodorou holds a bachelor's degree from Ithaca College and graduate education from Cornell University.

About CovagenCovagen develops bispecific FynomAbs™ by fusing its human Fynomer™ binding proteins to antibodies resulting in therapeutics with novel modes-of-action and enhanced efficacy in the treatment of inflammatory diseases and cancer. The ability to fuse Fynomers™ to multiple sites on an antibody allows Covagen to create FynomAbs™ with tailored architecture to maximize efficacy. FynomAbs™ maintain the advantageous drug-like properties of antibodies such as excellent stability and long half-life. Covagen is actively moving COVA322, its lead bispecific anti-TNF/IL-17A FynomAb™, through development and expects to initiate a Phase I/IIa trial in patients with psoriasis in the first quarter of 2014.

For more information, please visit www.covagen.com.Corporate Contact:

Media Contact:Julian Bertschinger, Ph.D.Matt Middleman, M.D.Chief Executive OfficerRusso PartnersTel: +41 (0) 44 732 4Tel: +1 212 845 4272info@covagen.commatt.middleman@russopartnersllc.com 


'/>"/>
SOURCE Covagen
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. IDEXX Laboratories Names Jeffrey Fiarman Executive Vice President and General Counsel
2. Collegium Pharmaceutical Names Douglas Carlson to Vice President of Business Development
3. Quest Diagnostics Names Sukumar Nagendran, M.D., Vice President, Medical Affairs
4. Halozyme Therapeutics Names Matt Posard to Board of Directors
5. Array BioPharma Names Michael N. Needle, M.D. As Chief Medical Officer
6. Bausch + Lomb Names Robert Bertolini President And Chief Financial Officer
7. Tandem Diabetes Care Names Lonnie Smith As Chairman Of The Board
8. PeriGen, Inc. Names American Journal of OBGYN Editor-In-Chief Thomas J. Garite MD, Chief Clinical Officer
9. Dynamic Healthcare Services Names Senior Level Management Team
10. Hello Health Inc. Names Barry Holleman Executive Vice President, Chief Operating Officer
11. SkilaMederi Names Ray Joske as Chief Commercial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/7/2017)...  Diplomat Specialty Infusion Group, a brand of Diplomat Pharmacy, Inc. ... Iowa location. The Iowa ... an ISO 7 cleanroom—the standard needed to compound intravenous (IV) nutrition ... of pollutants. "Our new cleanroom ... serve our Iowa patients," said Phil ...
(Date:6/1/2017)... 2017 Nutriceutical Holdings (NH), parent company of ... and KD Pharma Group have decided to join forces ... Pharma Group. KD Pharma Group will become the largest ... the entire company. "We believe we have ... to growing the NH companies by providing us with ...
(Date:5/26/2017)... 2017  Endo International plc (NASDAQ: ENDP ) ... will represent the Company in a fireside chat at Goldman ... June 13, 2017 at 10:40 a.m. PT / 1:40 p.m. ... Rancho Palos Verdes, CA. ... be available on the Company,s website at http://www.endo.com/investors/overview . ...
Breaking Medicine Technology:
(Date:6/24/2017)... ... June 24, 2017 , ... Dr. ... 217 Portion Road in Lake Ronkonkoma, Dental365 offers patients high-quality and affordable routine ... visits to the dentist fit into their patients’ busy lifestyles. Dental365 also gladly ...
(Date:6/23/2017)... ... 2017 , ... "The Better Care Reconciliation Act (BCRA) falls ... people with all chronic conditions, including mental illnesses, while increasing the cost of ... Care Act (ACA) requirement that insurers cover pre-existing conditions, it does not require ...
(Date:6/23/2017)... ... 2017 , ... The Military Officers Association of America (MOAA) announced its support ... retired Marine Col. Thomas G. Bowman. , Bowman currently serves as the staff director ... with the issues and challenges veterans face with the VA. Following a 30-year career ...
(Date:6/23/2017)... ... June 23, 2017 , ... Goodcents Deli Fresh Subs today announced the opening ... 4210 SW 21st St. Topeka, Kan. 66604 (near 21st and Gage). It is owned ... owns three other locations in the Topeka and Bonner Springs, Kan. area. , ...
(Date:6/23/2017)... ... June 23, 2017 , ... 21 Middle East and South ... selected 21 leaders from government, business and civil society in 11 countries across the ... this fall, engaging in a transformative exchange of knowledge and ideas with the leading ...
Breaking Medicine News(10 mins):